Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Sep 21, 2023
Emerging Company Profile

hC Bio: restoring protein function with tRNA therapies

Its sights set on cancer and rare diseases, Boston-based hC Bioscience hopes to take its first engineered tRNA therapy into the clinic next year 
BioCentury | Sep 12, 2023
Distillery Therapeutics

Targeting AHCY for APC-deficient CRC

BioCentury | Jan 11, 2020
Targets & Mechanisms

Colitis-associated somatic mutations yield new colorectal cancer target

Kyoto University suggests colitis-linked mutations may inhibit disease-associated colorectal cancer
BioCentury | Feb 28, 2019
Distillery Therapeutics

Cancer

BioCentury | Dec 4, 2014
Distillery Therapeutics

Indication: Cancer

BioCentury | Jun 26, 2014
Distillery Techniques

Technology: Drug delivery

BioCentury | Jul 25, 2013
Distillery Techniques

Technology: Disease models

BioCentury | Apr 18, 2013
Cover Story

Targeting tankyrase

Items per page:
1 - 10 of 50